Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2710931 | 0.86 | NT5E (0.48) | NT5EL3MBTL1CCR1CCR8MAP4K4 | |
| SCHEMBL1258312 | 0.83 | KCNH2 (0.47) | NT5EL3MBTL1KDM4ELMNACYP1A2 | |
| SCHEMBL6354888 | 0.81 | KDM4E (0.38) | NT5EL3MBTL1MAP4K4CSNK2A1HIPK4 | |
| SCHEMBL2709776 | 0.81 | PRKD3 (0.40) | NT5EL3MBTL1MAP4K4CSNK2A1HIPK4 | |
| SCHEMBL2711191 | 0.81 | ELANE (0.48) | NT5EL3MBTL1NPSR1MAPTKDM4E | |
| SCHEMBL3628877 | 0.81 | NT5E (0.44) | NT5EL3MBTL1CCR1CCR8NPSR1 | |
| SCHEMBL3631708 | 0.81 | ENPP1 (0.56) | NT5EL3MBTL1CCR1CCR8MAP4K4 | |
| SCHEMBL3628880 | 0.81 | NT5E (0.44) | NT5EL3MBTL1CCR1CCR8NPSR1 | |
| SCHEMBL19584236 | 0.81 | NT5E (0.36) | NT5EMAP4K4CSNK2A1HIPK4CLK4 | |
| SCHEMBL30827893 | 0.80 | PDE10A (0.42) | L3MBTL1CCR1CCR8PDE10APTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010089341-A1 | NOVEL VANCOMYCIN-AMINOQUINOLINE HYBRID MOLECULES THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | PALUMED S.A. (FR) | 2010-08-12 | — | — | WO | disclosed |
| EP-1308439-B1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | disclosed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | NT5E 1422/4885L3MBTL1 2628/4885CCR1 2116/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | NT5E 1422/4885L3MBTL1 2628/4885CCR1 2116/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | NT5E 1718/4885L3MBTL1 2337/4885CCR1 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.